Abstract
104. Association Between Serum C-Reactive Protein, Positive and Negative Symptoms of Psychosis in a General Population-Based Birth Cohort
Highlights
The immune pathogenesis story of schizophrenia is gathering momentum, with increasing evidence from genetic, circulating biomarker and neuropathological studies
Data will include evidence of a prenatal immune activation and the potential transgenerational transmission of behavioural and neuronal abnormalities, co-variation of gene sets associated with both increased risk of schizophrenia and immune function together with CRP and peripheral inflammatory cytokine association with symptom profiles in both larger population and clinical samples
Depressive symptoms are common in schizophrenia, hallucinations and delusional beliefs common in mood disorders and anhedonia a cross diagnostic challenge Methods: This presentation will include data of altered circulating proinflammatory markers from recently completed meta-analysis in first episode psychosis, established schizophrenia and bipolar disorder, highlighting the potential pluripotent inflammation pathway to mental disorders and outline a circulating cytokine profile at the onset and development of mental disorder as related to symptom specific profiles
Summary
Even if there have been effective antipsychotic treatments for more than fifty years, the implementation of these treatments in clinical practice is still far from optimal, and a significant amount of patients with schizophrenia show poor outcomes. Several questions still demand answer in the field It is unclear how long we should wait before changing an antipsychotic that has not been fully effective, how long we have to wait before starting clozapine in FES, whether we can identify who will respond better to current treatments using biological markers including neuroimaging, and how to improve adherence and functional prognosis after clinical remission is achieved. Based on previous results from the EUFEST study, all patients received amisulpride as a first step For those not achieving remission after 4 weeks, OPTiMiSE compared in a randomised double-blind fashion the option of staying on amisulpride or moving to a drug with a different receptorbinding profile, olanzapine. This symposium offers an overview of the main results obtained in the project in all these areas, with special focus on their clinical and research implications
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
